Research ExplorerPublicationsMethylation-specific PCR for DNA-based detection of occult t...

Methylation-specific PCR for DNA-based detection of occult tumor cells in lymph nodes of prostate cancer patients.

Standard

Methylation-specific PCR for DNA-based detection of occult tumor cells in lymph nodes of prostate cancer patients. / Köllermann, Jens; Müller, Markus; Goessl, Carsten; Krause, Hans; Helpap, Burkhard; Pantel, Klaus; Miller, Kurt.

In: EUR UROL, Vol. 44, No. 5, 5, 2003, p. 533-538.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Köllermann, J, Müller, M, Goessl, C, Krause, H, Helpap, B, Pantel, K & Miller, K 2003, 'Methylation-specific PCR for DNA-based detection of occult tumor cells in lymph nodes of prostate cancer patients.', EUR UROL, vol. 44, no. 5, 5, pp. 533-538. <http://www.ncbi.nlm.nih.gov/pubmed/14572750?dopt=Citation>

APA

Köllermann, J., Müller, M., Goessl, C., Krause, H., Helpap, B., Pantel, K., & Miller, K. (2003). Methylation-specific PCR for DNA-based detection of occult tumor cells in lymph nodes of prostate cancer patients. EUR UROL, 44(5), 533-538. [5]. http://www.ncbi.nlm.nih.gov/pubmed/14572750?dopt=Citation

Vancouver

Köllermann J, Müller M, Goessl C, Krause H, Helpap B, Pantel K et al. Methylation-specific PCR for DNA-based detection of occult tumor cells in lymph nodes of prostate cancer patients. EUR UROL. 2003;44(5):533-538. 5.

Bibtex

@article{b507bac91176459b8f2515defcbfda5e,
title = "Methylation-specific PCR for DNA-based detection of occult tumor cells in lymph nodes of prostate cancer patients.",
abstract = "OBJECTIVES: To assess the feasibility of methylation-specific PCR (MSP) for the detection of promoter hypermethylation of the detoxifying glutathione-S-transferase P1 gene (GSTP1) to detect occult prostate cancer cells in lymph nodes (LNs). METHODS: Paraffin-embedded pelvic LNs from 20 patients with pT2pN0M0R0 prostate cancer who developed PSA relapse were assessed by MSP. In 18 of the patients, samples of the primary tumor were obtained for MSP. In 19 patients, bone marrow (BM) aspirates were analyzed preoperatively for disseminated tumor cells by immunocytochemistry (mAb A45-B/B3). In 16 patients, biopsies of the anastomotic region were performed following PSA relapse. As a negative control GSTP1 methylation status was also assessed in LNs from 9 patients for whom an autopsy was performed for non-cancer-related causes. RESULTS: All primary tumors displayed GSTP1 hypermethylation (HM). Preoperative BM assessment showed disseminated tumor cells in 8/20 cases (40%). In 4 patients, biopsies of the vesico-urethral anastomosis showed local tumor recurrence. The LNs in the cancer patients showed GSTP1 HM in 18/20 cases (90%) versus 1/9 patients (11.1%) in the non-cancer cohort (p",
author = "Jens K{\"o}llermann and Markus M{\"u}ller and Carsten Goessl and Hans Krause and Burkhard Helpap and Klaus Pantel and Kurt Miller",
year = "2003",
language = "Deutsch",
volume = "44",
pages = "533--538",
journal = "EUR UROL",
issn = "0302-2838",
publisher = "Elsevier",
number = "5",

}

RIS

TY - JOUR

T1 - Methylation-specific PCR for DNA-based detection of occult tumor cells in lymph nodes of prostate cancer patients.

AU - Köllermann, Jens

AU - Müller, Markus

AU - Goessl, Carsten

AU - Krause, Hans

AU - Helpap, Burkhard

AU - Pantel, Klaus

AU - Miller, Kurt

PY - 2003

Y1 - 2003

N2 - OBJECTIVES: To assess the feasibility of methylation-specific PCR (MSP) for the detection of promoter hypermethylation of the detoxifying glutathione-S-transferase P1 gene (GSTP1) to detect occult prostate cancer cells in lymph nodes (LNs). METHODS: Paraffin-embedded pelvic LNs from 20 patients with pT2pN0M0R0 prostate cancer who developed PSA relapse were assessed by MSP. In 18 of the patients, samples of the primary tumor were obtained for MSP. In 19 patients, bone marrow (BM) aspirates were analyzed preoperatively for disseminated tumor cells by immunocytochemistry (mAb A45-B/B3). In 16 patients, biopsies of the anastomotic region were performed following PSA relapse. As a negative control GSTP1 methylation status was also assessed in LNs from 9 patients for whom an autopsy was performed for non-cancer-related causes. RESULTS: All primary tumors displayed GSTP1 hypermethylation (HM). Preoperative BM assessment showed disseminated tumor cells in 8/20 cases (40%). In 4 patients, biopsies of the vesico-urethral anastomosis showed local tumor recurrence. The LNs in the cancer patients showed GSTP1 HM in 18/20 cases (90%) versus 1/9 patients (11.1%) in the non-cancer cohort (p

AB - OBJECTIVES: To assess the feasibility of methylation-specific PCR (MSP) for the detection of promoter hypermethylation of the detoxifying glutathione-S-transferase P1 gene (GSTP1) to detect occult prostate cancer cells in lymph nodes (LNs). METHODS: Paraffin-embedded pelvic LNs from 20 patients with pT2pN0M0R0 prostate cancer who developed PSA relapse were assessed by MSP. In 18 of the patients, samples of the primary tumor were obtained for MSP. In 19 patients, bone marrow (BM) aspirates were analyzed preoperatively for disseminated tumor cells by immunocytochemistry (mAb A45-B/B3). In 16 patients, biopsies of the anastomotic region were performed following PSA relapse. As a negative control GSTP1 methylation status was also assessed in LNs from 9 patients for whom an autopsy was performed for non-cancer-related causes. RESULTS: All primary tumors displayed GSTP1 hypermethylation (HM). Preoperative BM assessment showed disseminated tumor cells in 8/20 cases (40%). In 4 patients, biopsies of the vesico-urethral anastomosis showed local tumor recurrence. The LNs in the cancer patients showed GSTP1 HM in 18/20 cases (90%) versus 1/9 patients (11.1%) in the non-cancer cohort (p

M3 - SCORING: Zeitschriftenaufsatz

VL - 44

SP - 533

EP - 538

JO - EUR UROL

JF - EUR UROL

SN - 0302-2838

IS - 5

M1 - 5

ER -